Other CVD-related medications, including SGLT-2 inhibitors (4.4% vs 3.2%, adj P = .030), diuretics (28.8% vs 25.4, adj P = .015), beta-blockers (34.8% vs 31.6%, adj P = .030), and cholesterol-lowering medications (70.2% vs 65.1%, P = .001) were prescribed more in the HT group. This evidence concerns the gene SLC5A2 and hematocrit.